0	14	Quantification	quantification	NN
15	17	of	of	IN
18	25	vitamin	vitamin	NN
26	27	D	D	NNP
28	36	receptor	receptor	NN
37	41	mRNA	mrna	NN
42	44	by	by	IN
45	56	competitive	competitive	JJ
57	67	polymerase	polymerase	NN
68	73	chain	chain	NN
74	82	reaction	reaction	NN
83	85	in	in	IN
86	90	PBMC	PBMC	NNP
90	91	:	:	:
92	96	lack	lack	NN
97	99	of	of	IN
100	114	correspondence	correspondence	NN
115	119	with	with	IN
120	126	common	common	JJ
127	134	allelic	allelic	JJ
135	143	variants	variant	NNS
143	144	.	.	.

146	148	It	it	PRP
149	152	has	have	VBZ
153	157	been	be	VBN
158	166	recently	recently	RB
167	174	claimed	claim	VBN
175	179	that	that	IN
180	192	polymorphism	polymorphism	NN
193	196	for	for	IN
197	200	the	the	DT
201	208	vitamin	vitamin	NN
209	210	D	D	NNP
211	219	receptor	receptor	NN
220	221	(	(	(
221	224	VDR	VDR	NNP
224	225	)	)	)
226	236	influences	influence	VBZ
237	244	several	several	JJ
245	252	aspects	aspect	NNS
253	255	of	of	IN
256	263	calcium	calcium	NN
264	267	and	and	CC
268	272	bone	bone	NN
273	283	metabolism	metabolism	NN
283	284	.	.	.

285	287	To	to	TO
288	296	evaluate	evaluate	VB
297	300	the	the	DT
301	312	physiologic	physiologic	JJ
313	325	plausibility	plausibility	NN
326	328	of	of	IN
329	334	these	these	DT
335	341	claims	claim	NNS
341	342	,	,	,
343	345	we	we	PRP
346	354	compared	compare	VBD
355	358	the	the	DT
359	368	abundance	abundance	NN
369	371	of	of	IN
372	375	the	the	DT
376	379	VDR	VDR	NNP
380	384	mRNA	mRNA	NNP
385	387	in	in	IN
388	398	peripheral	peripheral	JJ
399	404	blood	blood	NN
405	416	mononuclear	mononuclear	JJ
417	422	cells	cell	NNS
423	424	(	(	(
424	429	PBMCs	PBMC	NNP
429	430	)	)	)
431	438	between	between	IN
439	448	different	different	JJ
449	452	VDR	vdr	NN
453	462	genotypes	genotype	NNS
463	468	using	use	VBG
469	470	a	a	DT
471	483	quantitative	quantitative	JJ
484	491	reverse	reverse	JJ
492	503	transcribed	transcribe	VBN
504	514	polymerase	polymerase	NN
515	520	chain	chain	NN
521	535	reaction-based	reaction-based	JJ
536	542	method	method	NN
542	543	.	.	.

544	547	The	the	DT
548	554	method	method	NN
555	557	is	be	VBZ
558	563	based	base	VBN
564	566	on	on	IN
567	570	the	the	DT
571	586	coamplification	coamplification	NN
587	589	of	of	IN
590	593	VDR	VDR	NNP
594	598	cDNA	cDNA	NNP
599	602	and	and	CC
603	605	an	an	DT
606	614	internal	internal	JJ
615	623	standard	standard	NN
624	634	consisting	consist	VBG
635	637	of	of	IN
638	643	known	known	JJ
644	658	concentrations	concentration	NNS
659	661	of	of	IN
662	663	a	a	DT
664	669	human	human	JJ
670	673	VDR	VDR	NNP
674	678	CDNA	cdna	NN
679	686	mutated	mutate	VBN
687	689	at	at	IN
690	691	a	a	DT
692	697	BglII	BglII	NNP
698	709	restriction	restriction	NN
710	714	site	site	NN
714	715	;	;	:
716	719	the	the	DT
720	730	interassay	interassay	JJ
731	742	coefficient	coefficient	NN
743	745	of	of	IN
746	755	variation	variation	NN
756	758	is	be	VBZ
759	761	11	11	CD
761	762	%	%	NN
762	763	.	.	.

764	766	To	to	TO
767	775	validate	validate	VB
776	779	the	the	DT
780	786	method	method	NN
786	787	,	,	,
788	790	we	we	PRP
791	795	made	make	VBD
796	799	use	use	NN
800	802	of	of	IN
803	810	earlier	early	JJR
811	819	receptor	receptor	NN
820	827	binding	binding	NN
828	835	studies	study	NNS
836	846	indicating	indicate	VBG
847	851	that	that	IN
852	858	normal	normal	JJ
859	864	human	human	JJ
865	874	monocytes	monocyte	NNS
875	878	and	and	CC
879	888	activated	activate	VBN
888	889	,	,	,
890	893	but	but	CC
894	897	not	not	RB
898	905	resting	rest	VBG
905	906	,	,	,
907	918	lymphocytes	lymphocyte	NNS
919	928	expressed	express	VBD
929	932	the	the	DT
933	936	VDR	vdr	NN
936	937	.	.	.

938	941	The	the	DT
942	955	concentration	concentration	NN
956	958	of	of	IN
959	962	the	the	DT
963	966	VDR	VDR	NNP
967	971	mRNA	mRNA	NNP
972	975	was	be	VBD
976	982	10(-8)	10(-8)	CD
983	985	to	to	TO
986	992	10(-7)	10(-7)	CD
993	996	g/g	g/g	NN
997	999	of	of	IN
1000	1005	total	total	JJ
1006	1009	RNA	RNA	NNP
1010	1012	in	in	IN
1013	1024	cell-sorted	cell-sorted	JJ
1025	1034	monocytes	monocyte	NNS
1035	1038	and	and	CC
1039	1041	in	in	IN
1042	1044	in	in	FW
1045	1050	vitro	vitro	FW
1051	1060	activated	activate	VBN
1061	1072	lymphocytes	lymphocyte	NNS
1072	1073	,	,	,
1074	1077	but	but	CC
1078	1082	only	only	RB
1083	1090	10(-12)	10(-12)	CD
1091	1094	g/g	g/g	NN
1095	1097	of	of	IN
1098	1103	total	total	JJ
1104	1108	mRNA	mrna	NN
1109	1111	in	in	IN
1112	1119	resting	rest	VBG
1120	1131	lymphocytes	lymphocyte	NNS
1131	1132	,	,	,
1133	1145	establishing	establish	VBG
1146	1150	that	that	IN
1151	1154	the	the	DT
1155	1158	VDR	VDR	NNP
1159	1163	mRNA	mRNA	NNP
1164	1174	determined	determine	VBN
1175	1177	by	by	IN
1178	1181	our	our	PRP$
1182	1188	method	method	NN
1189	1191	in	in	IN
1192	1197	PBMCs	PBMC	NNP
1198	1200	is	be	VBZ
1201	1204	due	due	JJ
1205	1207	to	to	TO
1208	1220	constitutive	constitutive	JJ
1221	1231	expression	expression	NN
1232	1234	in	in	IN
1235	1244	monocytes	monocyte	NNS
1244	1245	.	.	.

1246	1255	Following	follow	VBG
1256	1258	an	an	DT
1259	1266	initial	initial	JJ
1267	1275	genotype	genotype	NN
1276	1285	screening	screening	NN
1286	1288	of	of	IN
1289	1291	85	85	CD
1292	1298	normal	normal	JJ
1299	1309	volunteers	volunteer	NNS
1310	1312	by	by	IN
1313	1323	polymerase	polymerase	NN
1324	1329	chain	chain	NN
1330	1338	reaction	reaction	NN
1339	1341	or	or	CC
1342	1353	restriction	restriction	NN
1354	1362	fragment	fragment	NN
1363	1369	length	length	NN
1370	1382	polymorphism	polymorphism	NN
1383	1391	analysis	analysis	NN
1391	1392	,	,	,
1393	1395	14	14	CD
1396	1407	individuals	individual	NNS
1408	1412	with	with	IN
1413	1416	the	the	DT
1417	1419	Bb	Bb	NNP
1420	1428	genotype	genotype	NN
1428	1429	,	,	,
1430	1432	12	12	CD
1433	1437	with	with	IN
1438	1441	the	the	DT
1442	1444	bb	bb	NN
1445	1453	genotype	genotype	NN
1453	1454	,	,	,
1455	1458	and	and	CC
1459	1461	12	12	CD
1462	1466	with	with	IN
1467	1470	the	the	DT
1471	1473	BB	BB	NNP
1474	1482	genotype	genotype	NN
1483	1487	were	be	VBD
1488	1496	selected	select	VBN
1496	1497	.	.	.

1498	1501	The	the	DT
1502	1515	concentration	concentration	NN
1516	1518	of	of	IN
1519	1522	the	the	DT
1523	1526	VDR	VDR	NNP
1527	1531	mRNA	mRNA	NNP
1531	1532	,	,	,
1533	1542	corrected	correct	VBN
1543	1546	for	for	IN
1547	1550	the	the	DT
1551	1557	number	number	NN
1558	1560	of	of	IN
1561	1570	monocytes	monocyte	NNS
1570	1571	,	,	,
1572	1575	was	be	VBD
1576	1583	similar	similar	JJ
1584	1589	among	among	IN
1590	1593	the	the	DT
1594	1599	three	three	CD
1600	1608	genotype	genotype	NN
1609	1615	groups	group	NNS
1615	1616	,	,	,
1617	1619	as	as	IN
1620	1624	were	be	VBD
1625	1628	the	the	DT
1629	1634	other	other	JJ
1635	1644	variables	variable	NNS
1645	1653	examined	examine	VBN
1653	1654	:	:	:
1655	1660	serum	serum	NN
1661	1671	calcitriol	calcitriol	NN
1671	1672	,	,	,
1673	1678	serum	serum	NN
1679	1690	osteocalcin	osteocalcin	NN
1690	1691	,	,	,
1692	1695	and	and	CC
1696	1705	vertebral	vertebral	JJ
1706	1709	and	and	CC
1710	1713	hip	hip	NN
1714	1718	bone	bone	NN
1719	1726	density	density	NN
1726	1727	.	.	.

1728	1730	We	we	PRP
1731	1739	conclude	conclude	VBP
1740	1744	that	that	IN
1745	1748	VDR	VDR	NNP
1749	1761	polymorphism	polymorphism	NN
1762	1766	does	do	VBZ
1767	1770	not	not	RB
1771	1777	affect	affect	VB
1778	1781	the	the	DT
1782	1791	abundance	abundance	NN
1792	1794	of	of	IN
1795	1798	the	the	DT
1799	1802	VDR	VDR	NNP
1803	1807	mRNA	mRNA	NNP
1807	1808	.	.	.